PUBLISHED DATE : Jun 2022 | Pages : 299
Fill out your details & get your free sample
Global Proteomics Market Size, Share, & Trends Analysis Report by
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2027
299 Pages
80 Tables
149 Charts
5 Regions
18 Countries
36 Companies
4 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 50.69 Billion |
| Market Size (2021) | USD 25.13 billion |
| CAGR (2021-2027) | 12.41% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Product, Application, End-User, and Geography |
| Geographic Analysis | North America, Europe, APAC, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, Germany, France, UK, Italy, Spain, Japan, China, South Korea, Australia, India, Brazil, Mexico, Argentina, Turkey, South Africa, and Saudi Arabia |
The global proteomics market was valued at USD 25.13 billion in 2021 and is expected to reach USD 50.69 billion by 2027, growing at a CAGR of 12.41%. Increasing awareness among the people regarding applications of proteomics in drug discovery and development, biomarker discovery, and clinical diagnostics for disease diagnosis and treatment is propelling the market's growth. Many private and public research organizations focus on developing proteomics based on spectrometry.
Proteomics is the extensive study of proteins, a rapidly growing field in disease diagnosis. It identifies disease-associated proteins and studies their function, structure, and expression. Proteomics researchers primarily rely on sophisticated technology to deliver actionable insights to advance the field because of the number of complexities in proteomics. Proteomics is a key tool in medical research because it allows studying large-scale proteins from various biological samples to discover new protein biomarkers for different disease conditions.
Proteomics allows for the discovery of new protein biomarkers for diagnostic applications and the investigation of novel molecular targets for medication development and discovery. Protein expression profiling, targeted protein quantification, protein-protein interaction analysis, and post-translational modifications are all possible using proteomics. Proteomics has demonstrated its utility in biomarker identification, medication development, and precision medicine.
The impact of COVID-19 is also seen in the proteomics market's growth. There has been increased research on diagnostics, biomarker discovery, and drug discovery and development against COVID-19. It has accelerated the involvement of proteomics. Several large and small companies have constantly been coming up with immunoassay kits to detect COVID-19 rapidly. Along with companies, many public/private research organizations and research institutes also increased the research on the coronavirus involving the proteomics approach extensively.
Proteomics plays a considerable role in drug development, and therefore, many drug manufacturers have started their proteomics divisions that fuel the growth of the global proteomics market.
Existing technologies have several drawbacks, including a lack of specificity, especially in high-multiplex assays, a lack of sensitivity, and a lack of precision; a limited dynamic range (the ability to measure a wide range of concentrations reliably and simultaneously); a high sample consumption requirement; a lack of scalability; a low throughput; data complexity; and a high cost. This scenario is changing over time and will enhance the scope of proteomics.
Proteomics technologies in the market include spectrometry, microarray, chromatography, and reagents used for proteomic analysis. The majority of proteomic analysis primarily relies on an expensive and complex analysis of proteome complexity at the level of amino acid variants, which have the potential to generate important biological insights.
Nanoproteomics offers real-time multiplexed analysis, rapid and miniatured assay, low sample consumption, and high sensitivity, thereby finding many applications for proteomic investigations.
The growing prominence of nanoproteomics offers significant growth opportunities for players in the market. Nanoproteomics is still in its early stage of enabling broad biomedical applications. In the upcoming years, continuous technological advancement in this field is anticipated. The growing prominence of nanoproteomics offers significant growth opportunities for players in this market.
BGI, a China-based company, has extensive experience in nanoproteomics. The company offers a nanoproteomics service, serving in more than 66 countries. Seer company's photograph product suite, an integrated solution, consists of the company's proprietary engineered nanoparticles, consumables, automation instrument, and software that allows proteomics studies. It reduces the complexity of traditional proteomics. It has commercialized its services using the proteograph product suite with North America, Europe, and the Asia Pacific providers.
The consumables and reagents segment has the largest market share accounting for 77.08% in 2021. For several decades, many companies have included both small and large companies, relentlessly working to bring more reagents and consumables used in all the areas of proteomics application in the initial step, which is during the sample preparation. Many vital companies offer a wide range of consumables and reagents, such as Agilent Technologies, Bio-Rad Laboratories, and Thermo Fisher Scientific. An increase in the reagent's portfolio is evitable with the increasing proteomics research worldwide. These factors make the consumables and reagents segment the highest revenue maker, with $19.37 billion in 2021.
Most key companies offer a wide range of instruments for microarray, spectrometry, chromatography, electrophoresis, surface plasma resonance, and x-ray crystallography. With the increasing research on biomarker discovery and drug discovery and development, several pharmaceutical companies and academic & research institutes are expected to increase the implementation of instruments and software in their laboratories. Hence, the instruments & software segment is expected to increase in the forecast period with a CAGR of 13%.
Among all the end-users, the pharmaceutical and biotechnology companies segment is growing due to the development and demand of the increasing diagnostic for drug development. The surge in the use of proteomic technology is also due to the rising adoption of precision medicine driven by biomarkers identification and discovery in response to the increasing prevalence of chronic diseases such as cancer mainly.
Several academic and research institutes are also the second major revenue generator in the proteomics market, increasing research on developing drugs and vaccines. Hospitals are also using proteomics technologies for disease diagnosis purposes. They either have their in-house pathology laboratory or collaborate with a diagnostic laboratory, and they get the diagnosis done by sending the samples. In collaboration or partnership with proteomics companies, several hospitals are enabling the companies to develop related proteomic technologies.
Forensic laboratories are also contributing and accounting for a good market share in growing the proteomics markets by receiving massive funding and investments to conduct research in forensic science for protein identification and biomarker discovery.
While Pharmaceutical and Biotechnology, companies are the highest revenue generator segment, with $11.76 billion in 2021. Academic & research institutes are the most significant users of proteomics technologies for various ongoing research activities in multiple dimensions: discovery, new technology innovations, better product advancements, academic training, etc. The Academic and Research institutes segment is expected to grow at the highest CAGR of 12.91%.
Increasing adoption of personalized medicine, increasing R&D expenditures for drug discovery, biomarker discovery, and biomarker-driven development of precision medicine are the major factors that drive the growth of the proteomics market worldwide.
Increasing awareness among the people regarding applications of proteomics in drug discovery and development, biomarker discovery, and clinical diagnostics for disease diagnosis and treatment is also propelling the market's growth. Some private and public research organizations focus on developing proteomics based on spectrometry.
In North America, Europe, and APAC region, increased funding by the government for the R&D activities boosts growth opportunities for the key players in the market to develop advanced proteomics diagnostics and instruments in the forecast period. However, in these regions, a lack of skilled professionals is limiting the growth of the proteomics market. In North America and APAC region, the introduction of nanotechnology in proteomics is trending and has shown vast opportunities for acceptance. For instance, in China, BGI Genomics is offering nano proteomics services.
Middle East, Africa, and Latin America are showing a growing focus on the adoption of precision medicine. The governments have taken several initiatives to accelerate the growth of the proteomics market in Latin America, the Middle East, and Africa. Also, the rising popularity of personalized medicine increased research on biomarkers and drug discovery, driving the proteomics market in Latin America, the Middle East, and Africa. However, stringent regulatory norms and the high cost of proteomics instruments, lack of funds and investments, lack of awareness about proteomics, and lack of skilled professionals are restraining these regions from adopting advanced proteomics approaches.
Vendors are divided into both manufacturers and service providers. The proteomics market is highly dynamic and competitive, with global, regional, and local players offering a wide range of proteomics solutions. Agilent Technologies, Bio-Rad Laboratories, Thermo-Fisher Scientific, Danaher, and PerkinElmer are the significant players in providing products in proteomics, whereas BGI Group is a substantial player in offering proteomics services.
The need for companies that provide proteomics services has drawn the attention of many researchers from laboratories that are not equipped with advanced technologies for proteomic research. This could be due to a lack of skilled professionals or in-house infrastructure, as increased demand for proteomics research. Many companies have emerged by providing protein identification, quantification, sequencing, purification, and custom assay services.
Frequently Asked Questions
HOW BIG IS THE GLOBAL PROTEOMICS MARKET?
The global proteomics market was valued at USD 25.13 billion in 2021 and is expected to reach USD 50.69 billion by 2027.
WHAT IS THE GROWTH RATE OF THE GLOBAL PROTEOMICS MARKET?
The global proteomics market is expected to grow at a CAGR of 12.41% during 2022-2027.
WHO ARE THE KEY PLAYERS IN THE GLOBAL PROTEOMICS MARKET?
Key players include Agilent Technologies, Bio-Rad Laboratories, Danaher, Thermo Fisher Scientific, PerkinElmer, and BGI Genomics.
WHAT ARE THE GROWTH FACTORS IN THE GLOBAL PROTEOMICS MARKET?
The increasing number of research and development activities in proteomics, rising prevalence of cancer and various genetic disorders, and growing focus on the development of precision medicine are the growth factors in the global proteomics market.
WHAT ARE THE LATEST TRENDS IN THE GLOBAL PROTEOMICS MARKET?
Development in mass spectrometry-based proteomics, Increasing Prominence of Nanoproteomics, and proteomics revolutionizing diabetes management are the latest trends in the market.
The global proteomics market was valued at USD 25.13 billion in 2021 and is expected to reach USD 50.69 billion by 2027, growing at a CAGR of 12.41%.
The following factors will drive the global proteomics market growth during the forecast period:
The study considers a detailed scenario of the present global proteomics market and its dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the industry.
Base Year: 2021
Forecast Year: 2022-2027
Key Vendors
Other Prominent Vendors by Product
Other Prominent Vendors by Service
Other Prominent Vendors by Product & Services
Market Segmentation by Product
Market Segmentation by Application
Market Segmentation by End-User
Regions
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY PRODUCT
4.3.2 MARKET SEGMENTATION BY APPLICATION
4.3.3 MARKET SEGMENTATION BY END USER
4.3.4 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
7.1.1 LOW-THROUGHPUT METHODS
7.1.2 HIGH-THROUGHPUT METHODS
8 MARKET OPPORTUNITIES & TRENDS
8.1 INCREASING PROMINENCE OF NANOPROTEOMICS
8.2 DEVELOPMENTS IN MASS SPECTROMETRY-BASED PROTEOMICS
8.3 PROMINENT ROLE OF PROTEOMICS IN DIABETES MANAGEMENT
9 MARKET GROWTH ENABLERS
9.1 RISING NUMBER OF R&D PROJECTS IN PROTEOMICS
9.2 INCREASING PREVALENCE OF CANCER AND VARIOUS GENETIC DISORDERS
9.3 GROWING FOCUS ON DEVELOPMENT OF PRECISION MEDICINE
10 MARKET RESTRAINTS
10.1 LIMITATIONS ASSOCIATED WITH ACCESSING PROTEOME
10.2 DEARTH OF SKILLED PROFESSIONALS
10.3 STRICT REGULATORY NORMS & HIGH COST OF INSTRUMENTS
11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.2.1 INSIGHTS BY PRODUCT
11.2.2 INSIGHTS BY APPLICATION
11.2.3 INSIGHTS BY END USERS
11.2.4 INSIGHTS BY GEOGRAPHY
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY
12 PRODUCT
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 CONSUMABLES & REAGENTS
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 MARKET BY GEOGRAPHY
12.4 INSTRUMENTS & SOFTWARE
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 MARKET BY GEOGRAPHY
12.5 SERVICES
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 MARKET BY GEOGRAPHY
13 APPLICATION
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 DRUG DISCOVERY & DEVELOPMENT AND TRANSLATIONAL RESEARCH
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MARKET BY GEOGRAPHY
13.4 CLINICAL APPLICATIONS
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
13.5 FORENSICS & APPLIED PROTEOMICS
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 MARKET BY GEOGRAPHY
14 END USER
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 ACADEMIC & RESEARCH INSTITUTES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 HOSPITALS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY
14.6 DIAGNOSTIC & FORENSIC LABORATORIES
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 MARKET BY GEOGRAPHY
15 GEOGRAPHY
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 GEOGRAPHIC OVERVIEW
16 NORTH AMERICA
16.1 MARKET OVERVIEW
16.2 MARKET SIZE & FORECAST
16.3 NORTH AMERICA: PRODUCT SEGMENTATION
16.4 NORTH AMERICA: APPLICATION SEGMENTATION
16.5 NORTH AMERICA: END-USER SEGMENTATION
16.6 KEY COUNTRIES
16.6.1 US: MARKET SIZE & FORECAST
16.6.2 CANADA: MARKET SIZE & FORECAST
17 EUROPE
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.3 EUROPE: PRODUCT SEGMENTATION
17.4 EUROPE: APPLICATION SEGMENTATION
17.5 EUROPE: END-USER SEGMENTATION
17.6 KEY COUNTRIES
17.6.1 GERMANY: MARKET SIZE & FORECAST
17.6.2 FRANCE: MARKET SIZE & FORECAST
17.6.3 UK: MARKET SIZE & FORECAST
17.6.4 ITALY: MARKET SIZE & FORECAST
17.6.5 SPAIN: MARKET SIZE & FORECAST
18 APAC
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 APAC: PRODUCT SEGMENTATION
18.4 APAC: APPLICATION SEGMENTATION
18.5 APAC: END-USER SEGMENTATION
18.6 KEY COUNTRIES
18.6.1 JAPAN: MARKET SIZE & FORECAST
18.6.2 CHINA: MARKET SIZE & FORECAST
18.6.3 SOUTH KOREA: MARKET SIZE & FORECAST
18.6.4 AUSTRALIA: MARKET SIZE & FORECAST
18.6.5 INDIA: MARKET SIZE & FORECAST
19 LATIN AMERICA
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.3 LATIN AMERICA: PRODUCT SEGMENTATION
19.4 LATIN AMERICA: APPLICATION SEGMENTATION
19.5 LATIN AMERICA: END-USER SEGMENTATION
19.6 KEY COUNTRIES
19.6.1 BRAZIL: MARKET SIZE & FORECAST
19.6.2 MEXICO: MARKET SIZE & FORECAST
19.6.3 ARGENTINA: MARKET SIZE & FORECAST
20 MIDDLE EAST & AFRICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.3 MIDDLE EAST & AFRICA: PRODUCT SEGMENTATION
20.4 MIDDLE EAST & AFRICA: APPLICATION SEGMENTATION
20.5 MIDDLE EAST & AFRICA: END-USER SEGMENTATION
20.6 KEY COUNTRIES
20.6.1 TURKEY: MARKET SIZE & FORECAST
20.6.2 SOUTH AFRICA: MARKET SIZE & FORECAST
20.6.3 SAUDI ARABIA: MARKET SIZE & FORECAST
21 COMPETITIVE LANDSCAPE
21.1 COMPETITION OVERVIEW
21.2 MARKET SHARE ANALYSIS
21.2.1 AGILENT TECHNOLOGIES
21.2.2 BIO-RAD LABORATORIES
21.2.3 THERMO FISHER SCIENTIFIC
21.2.4 DANAHER
21.2.5 PERKINELMER
21.2.6 BGI GROUP
22 KEY COMPANY PROFILES
22.1 AGILENT TECHNOLOGIES
22.1.1 BUSINESS OVERVIEW
22.1.2 PRODUCT OFFERINGS
22.1.3 KEY STRATEGIES
22.1.4 KEY STRENGTHS
22.1.5 KEY OPPORTUNITIES
22.2 BIO-RAD LABORATORIES
22.2.1 BUSINESS OVERVIEW
22.2.2 PRODUCT OFFERINGS
22.2.3 KEY STRATEGIES
22.2.4 KEY STRENGTHS
22.2.5 KEY OPPORTUNITIES
22.3 DANAHER
22.3.1 BUSINESS OVERVIEW
22.3.2 PRODUCT OFFERINGS
22.3.3 KEY STRATEGIES
22.3.4 KEY STRENGTHS
22.3.5 KEY OPPORTUNITIES
22.4 THERMO FISHER SCIENTIFIC
22.4.1 BUSINESS OVERVIEW
22.4.2 PRODUCT OFFERINGS
22.4.3 KEY STRATEGIES
22.4.4 KEY STRENGTHS
22.4.5 KEY OPPORTUNITIES
22.5 PERKINELMER
22.5.1 BUSINESS OVERVIEW
22.5.2 PRODUCT OFFERINGS
22.5.3 KEY STRATEGIES
22.5.4 KEY STRENGTHS
22.5.5 KEY OPPORTUNITIES
22.6 BGI GROUP
22.6.1 BUSINESS OVERVIEW
22.6.2 PRODUCT OFFERINGS
22.6.3 KEY STRATEGIES
22.6.4 KEY STRENGTHS
22.6.5 KEY OPPORTUNITIES
23 OTHER PROMINENT VENDORS – BY PRODUCT
23.1 BRUKER
23.1.1 BUSINESS OVERVIEW
23.1.2 PRODUCT OFFERINGS
23.2 DIASORIN
23.2.1 BUSINESS OVERVIEW
23.2.2 PRODUCT OFFERINGS
23.3 HORIBA
23.3.1 BUSINESS OVERVIEW
23.3.2 PRODUCT OFFERINGS
23.4 ILLUMINA
23.4.1 BUSINESS OVERVIEW
23.4.2 PRODUCT OFFERINGS
23.5 INOVIQ
23.5.1 BUSINESS OVERVIEW
23.5.2 PRODUCT OFFERINGS
23.6 LI-COR BIOSCIENCES
23.6.1 BUSINESS OVERVIEW
23.6.2 PRODUCT OFFERINGS
23.7 NAUTILUS BIOTECHNOLOGY
23.7.1 BUSINESS OVERVIEW
23.7.2 PRODUCT OFFERINGS
23.8 PROTEOME FACTORY
23.8.1 BUSINESS OVERVIEW
23.8.2 PRODUCT OFFERINGS
23.9 QIAGEN
23.9.1 BUSINESS OVERVIEW
23.9.2 PRODUCT OFFERINGS
23.10 RHYTHM BIOSCIENCES
23.10.1 BUSINESS OVERVIEW
23.10.2 PRODUCT OFFERINGS
23.11 SHIMADZU SCIENTIFIC INSTRUMENTS
23.11.1 BUSINESS OVERVIEW
23.11.2 PRODUCT OFFERINGS
23.12 SEER
23.12.1 BUSINESS OVERVIEW
23.12.2 PRODUCT OFFERINGS
23.13 WATERS
23.13.1 BUSINESS OVERVIEW
23.13.2 PRODUCT OFFERINGS
24 SERVICE PROVIDERS
24.1 APPLIED BIOMICS
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.2 CREATIVE PROTEOMICS
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.3 POOCHON SCIENTIFIC
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.4 SOMALOGIC
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.5 VPROTEOMICS
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
25 PRODUCT & SERVICE PROVIDERS
25.1 ABCAM
25.1.1 BUSINESS OVERVIEW
25.1.2 PRODUCT & SERVICE OFFERINGS
25.2 ANTEOTECH
25.2.1 BUSINESS OVERVIEW
25.2.2 PRODUCT & SERVICE OFFERINGS
25.3 AYOXXA BIOSYSTEMS
25.3.1 BUSINESS OVERVIEW
25.3.2 PRODUCT & SERVICE OFFERINGS
25.4 BIOGNOSYS
25.4.1 BUSINESS OVERVIEW
25.4.2 PRODUCT & SERVICE OFFERINGS
25.5 GENEI LABORATORIES
25.5.1 BUSINESS OVERVIEW
25.5.2 PRODUCT OFFERINGS
25.6 GRACE BIO-LABS
25.6.1 BUSINESS OVERVIEW
25.6.2 PRODUCT & SERVICE OFFERINGS
25.7 ITSI-BIOSCIENCES
25.7.1 BUSINESS OVERVIEW
25.7.2 PRODUCT & SERVICE OFFERINGS
25.8 MSAID
25.8.1 BUSINESS OVERVIEW
25.8.2 PRODUCT & SERVICE OFFERINGS
25.9 OLINK
25.9.1 BUSINESS OVERVIEW
25.9.2 PRODUCT & SERVICE OFFERINGS
25.10 PROMEGA
25.10.1 BUSINESS OVERVIEW
25.10.2 PRODUCT & SERVICE OFFERINGS
25.11 PROTEOMICS INTERNATIONAL
25.11.1 BUSINESS OVERVIEW
25.11.2 PRODUCT & SERVICE OFFERINGS
25.12 QUANTERIX
25.12.1 BUSINESS OVERVIEW
25.12.2 PRODUCT & SERVICE OFFERINGS
26 REPORT SUMMARY
26.1 KEY TAKEAWAYS
26.2 STRATEGIC RECOMMENDATIONS
27 QUANTITATIVE SUMMARY
27.1 MARKET BY GEOGRAPHY
27.2 MARKET BY PRODUCT
27.3 MARKET BY APPLICATION
27.4 MARKET BY END USER
27.5 NORTH AMERICA BY PRODUCT
27.6 NORTH AMERICA BY APPLICATION
27.7 NORTH AMERICA BY END USER
27.8 EUROPE BY PRODUCT
27.9 EUROPE BY APPLICATION
27.10 EUROPE BY END USER
27.11 APAC BY PRODUCT
27.12 APAC BY APPLICATION
27.13 APAC BY END USER
27.14 LATIN AMERICA BY PRODUCT
27.15 LATIN AMERICA BY APPLICATION
27.16 LATIN AMERICA BY END USER
27.17 MIDDLE EAST & AFRICA BY PRODUCT
27.18 MIDDLE EAST & AFRICA BY APPLICATION
27.19 MIDDLE EAST & AFRICA BY END USER
28 APPENDIX
28.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL PROTEOMICS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 APPLICATION AREAS OF PROTEOMICS
EXHIBIT 4 FOCUS AREAS OF TYPICAL PROTEOMIC STUDIES
EXHIBIT 5 PROTEOMICS COMPANIES GENERATING HIGH REVENUES ($ MILLION)
EXHIBIT 6 IMPACT OF INCREASING PROMINENCE OF NANOPROTEOMICS
EXHIBIT 7 ADVANTAGES OF NANO PROTEOMICS
EXHIBIT 8 IMPACT OF DEVELOPMENTS IN MASS SPECTROMETRY-BASED PROTEOMICS
EXHIBIT 9 IMPACT OF PROMINENT ROLE OF PROTEOMICS IN DIABETES MANAGEMENT
EXHIBIT 10 PREVALENCE OF DIABETES AMONG ADULTS WORLDWIDE (20–79 AGE GROUP)
EXHIBIT 11 IMPACT OF RISING NUMBER OF R&D PROJECTS IN PROTEOMICS
EXHIBIT 12 IMPACT OF INCREASING PREVALENCE OF CANCER AND VARIOUS GENETIC DISORDERS
EXHIBIT 13 NUMBER OF NEW CASES OF TYPES OF CANCER IN 2020 (MILLION)
EXHIBIT 14 IMPACT OF GROWING FOCUS ON DEVELOPMENT OF PRECISION MEDICINE
EXHIBIT 15 IMPACT OF LIMITATIONS ASSOCIATED WITH ACCESSING PROTEOME
EXHIBIT 16 IMPACT OF DEARTH OF SKILLED PROFESSIONALS
EXHIBIT 17 KEY CHALLENGES IN SELECTING METHODS FOR PROTEOMICS RESEARCH
EXHIBIT 18 IMPACT OF STRICT REGULATORY NORMS & HIGH COST OF INSTRUMENTS
EXHIBIT 19 GLOBAL PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 20 GLOBAL PROTEOMICS MARKET BY PRODUCT 2021 & 2027 (%)
EXHIBIT 21 GLOBAL PROTEOMICS MARKET BY APPLICATION 2021 & 2027 (%)
EXHIBIT 22 GLOBAL PROTEOMICS MARKET BY END USER 2021 & 2027 (%)
EXHIBIT 23 GLOBAL PROTEOMICS MARKET BY GEOGRAPHY
EXHIBIT 24 FIVE FORCES ANALYSIS 2021
EXHIBIT 25 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 26 GLOBAL PROTEOMICS MARKET BY PRODUCT
EXHIBIT 27 GLOBAL PROTEOMICS MARKET BY PRODUCT
EXHIBIT 28 GLOBAL PROTEOMICS MARKET BY PRODUCT: GROWTH ANALYSIS
EXHIBIT 29 GLOBAL PROTEOMICS MARKET BY PRODUCT: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 30 GLOBAL PROTEOMICS MARKET BY PRODUCT: ABSOLUTE GROWTH (%)
EXHIBIT 31 REAGENTS OFFERED BY COMPANIES AND THEIR APPLICATIONS
EXHIBIT 32 LIST OF CONSUMABLES OFFERED BY BIO-RAD LABORATORIES
EXHIBIT 33 GLOBAL PROTEOMICS MARKET BY CONSUMABLES & REAGENTS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 34 GLOBAL PROTEOMICS MARKET BY CONSUMABLES & REAGENTS 2021–2027 ($ BILLION)
EXHIBIT 35 REAGENTS INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 36 GLOBAL PROTEOMICS MARKET BY INSTRUMENTS & SOFTWARE: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 37 GLOBAL PROTEOMICS MARKET BY INSTRUMENTS & SOFTWARE 2021–2027 ($ BILLION)
EXHIBIT 38 INSTRUMENTS INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 39 GLOBAL PROTEOMICS MARKET BY SERVICES 2021–2027 ($ BILLION)
EXHIBIT 40 GLOBAL PROTEOMICS MARKET BY SERVICES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 41 SERVICES INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 42 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 43 GLOBAL PROTEOMICS MARKET BY APPLICATION
EXHIBIT 44 GLOBAL PROTEOMICS MARKET BY APPLICATION
EXHIBIT 45 GROWTH ANALYSIS: PROTEOMICS MARKET BY APPLICATION
EXHIBIT 46 GLOBAL PROTEOMICS MARKET BY APPLICATION: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 47 GLOBAL PROTEOMICS MARKET BY APPLICATION – ABSOLUTE GROWTH (%)
EXHIBIT 48 GLOBAL PROTEOMICS MARKET BY DRUG DISCOVERY & DEVELOPMENT AND TRANSLATIONAL RESEARCH 2021–2027 ($ BILLION)
EXHIBIT 49 GLOBAL PROTEOMICS MARKET BY DDD & TR: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 50 DDD & TR INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 51 GLOBAL PROTEOMICS MARKET BY CLINICAL APPLICATIONS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL PROTEOMICS MARKET BY CLINICAL APPLICATIONS 2021–2027 ($ BILLION)
EXHIBIT 53 CLINICAL APPLICATIONS INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 54 GLOBAL PROTEOMICS MARKET BY FORENSICS & APPLIED PROTEOMICS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL PROTEOMICS MARKET BY FORENSICS & APPLIED PROTEOMICS 2021–2027 ($ BILLION)
EXHIBIT 56 FORENSICS & APPLIED PROTEOMICS INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 57 INCREMENTAL GROWTH BY END USER 2021 & 2027
EXHIBIT 58 GLOBAL PROTEOMICS MARKET BY END USER
EXHIBIT 59 GLOBAL PROTEOMICS MARKET BY END USER
EXHIBIT 60 GROWTH ANALYSIS: PROTEOMICS MARKET BY END USER
EXHIBIT 61 GLOBAL PROTEOMICS MARKET BY END USER: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 62 GLOBAL PROTEOMICS MARKET BY END USER: ABSOLUTE GROWTH (%)
EXHIBIT 63 APPLICATIONS OF PROTEOMICS IN VARIOUS SECTIONS OF PHARMACEUTICAL COMPANIES
EXHIBIT 64 CURRENT AND FUTURE STATE OF PROTEOMICS IN PHARMACEUTICAL INDUSTRY
EXHIBIT 65 GLOBAL PROTEOMICS MARKET BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 66 GLOBAL PROTEOMICS MARKET BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 2021–2027 ($ BILLION)
EXHIBIT 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 68 GLOBAL PROTEOMICS MARKET BY ACADEMIC & RESEARCH INSTITUTES 2021–2027 ($ BILLION)
EXHIBIT 69 GLOBAL PROTEOMICS MARKET BY ACADEMIC & RESEARCH INSTITUTES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 70 ACADEMIC & RESEARCH INSTITUTES INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 71 GLOBAL PROTEOMICS MARKET BY HOSPITALS: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 72 GLOBAL PROTEOMICS MARKET BY HOSPITALS 2021–2027 ($ BILLION)
EXHIBIT 73 HOSPITALS INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 74 GLOBAL PROTEOMICS MARKET BY DIAGNOSTIC & FORENSIC LABORATORIES: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 75 GLOBAL PROTEOMICS MARKET BY DIAGNOSTIC & FORENSIC LABORATORIES 2021–2027 ($ BILLION)
EXHIBIT 76 DIAGNOSTIC & FORENSIC LABORATORIES INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 77 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 78 GLOBAL PROTEOMICS MARKET BY GEOGRAPHY
EXHIBIT 79 GLOBAL PROTEOMICS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH ($ BILLION)
EXHIBIT 80 GLOBAL PROTEOMICS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH (%)
EXHIBIT 81 NORTH AMERICA PROTEOMICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 82 NORTH AMERICA PROTEOMICS MARKET: KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 83 NORTH AMERICA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 84 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 85 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 86 INCREMENTAL GROWTH BY END USER 2021 & 2027
EXHIBIT 87 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 88 PERSONALIZED MEDICINES WITH SPECIFIC BIOMARKERS: TOP 20% OF FDA APPROVALS BETWEEN 2005 & 2019
EXHIBIT 89 US PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 90 CIHR PROJECTED LEVERAGE BY PARTNER TYPE FOR PERSONALIZED MEDICINE BUSINESS
EXHIBIT 91 CANADA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 92 EUROPE PROTEOMICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 93 EUROPE PROTEOMICS MARKET: KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 94 EUROPE PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 95 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 96 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 97 INCREMENTAL GROWTH BY END USER 2021 & 2027
EXHIBIT 98 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 99 GERMANY PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 100 DISTRIBUTION OF SELECTED PROJECTS ACCORDING TO EQUIPMENT CATEGORIES 2016–2019
EXHIBIT 101 PROTEOMICS MARKET IN FRANCE 2021–2027 ($ BILLION)
EXHIBIT 102 UK PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 103 ITALY PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 104 SPAIN PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 105 APAC PROTEOMICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 106 APAC PROTEOMICS MARKET: KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 107 APAC PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 108 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 109 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 110 INCREMENTAL GROWTH BY END USER 2021 & 2027
EXHIBIT 111 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 112 JAPAN PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 113 CHINA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 114 SOUTH KOREA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 115 AUSTRALIA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 116 PROTEOMICS MARKET IN INDIA 2021–2027 ($ BILLION)
EXHIBIT 117 LATIN AMERICA PROTEOMICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 118 LATIN AMERICA PROTEOMICS MARKET: KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 119 LATIN AMERICA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 120 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 121 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 122 INCREMENTAL GROWTH BY END USER 2021 & 2027
EXHIBIT 123 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 124 BRAZIL PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 125 MEXICO PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 126 ARGENTINA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 127 MIDDLE EAST & AFRICA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 128 MIDDLE EAST & AFRICA PROTEOMICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 129 MIDDLE EAST & AFRICA PROTEOMICS MARKET: KEY COUNTRIES 2021 ($ BILLION)
EXHIBIT 130 INCREMENTAL GROWTH BY PRODUCT 2021 & 2027
EXHIBIT 131 INCREMENTAL GROWTH BY APPLICATION 2021 & 2027
EXHIBIT 132 INCREMENTAL GROWTH BY END USER 2021 & 2027
EXHIBIT 133 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 134 TURKEY PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 135 SOUTH AFRICA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 136 SAUDI ARABIA PROTEOMICS MARKET 2021–2027 ($ BILLION)
EXHIBIT 137 PURE & DIVERSIFIED COMPANIES IN GLOBAL PROTEOMICS MARKET
EXHIBIT 138 GLOBAL PROTEOMICS MARKET: MARKET DOMINANCE ANALYSIS
EXHIBIT 139 GLOBAL PROTEOMICS MARKET: KEY VENDORS CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 140 AGILENT TECHNOLOGIES: TOTAL REVENUE 2019–2021($ MILLION)
EXHIBIT 141 AGILENT TECHNOLOGIES: SALES BREAKDOWN BY GEOGRAPHY ($ MILLION)
EXHIBIT 142 BIO-RAD LABORATORIES: TOTAL REVENUE 2019–2021($ MILLION)
EXHIBIT 143 BIO-RAD LABORATORIES: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 144 BIO-RAD LABORATORIES: SALES BREAKDOWN BY GEOGRAPHY ($ MILLION)
EXHIBIT 145 THERMO FISHER SCIENTIFIC: TOTAL REVENUE 2019–2021($ MILLION)
EXHIBIT 146 THERMO FISHER SCIENTIFIC: R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 147 THERMO FISHER SCIENTIFIC: SALES BREAKDOWN BY GEOGRAPHY ($ MILLION)
EXHIBIT 148 PERKINELMER: TOTAL REVENUE 2019–2021($ MILLION)
EXHIBIT 149 PERKINELMER: R&D EXPENDITURE 2019–2021($ MILLION)
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 GLOBAL DIABETES MARKET SIZE ($ MILLION)
TABLE 4 OVERVIEW OF PROTEOMIC TECHNIQUES USED TO REVEAL NOVEL BIOLOGY OF VARIOUS INFECTIOUS DISEASES
TABLE 5 LIST OF CANCER BIOMARKERS IDENTIFIED USING PROTEOMICS APPROACHES
TABLE 6 APPLICATIONS OF FORENSIC PROTEOMICS USING HUMAN SAMPLES
TABLE 7 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 8 BIO-RAD LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 9 DANAHER: MAJOR PRODUCT OFFERINGS
TABLE 10 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 11 PERKINELMER: MAJOR PRODUCT OFFERINGS
TABLE 12 BGI GROUP: MAJOR PRODUCT OFFERINGS
TABLE 13 BRUKER: MAJOR PRODUCT OFFERINGS
TABLE 14 DIASORIN: MAJOR PRODUCT OFFERINGS
TABLE 15 HORIBA: MAJOR PRODUCT OFFERINGS
TABLE 16 ILLUMINA: MAJOR PRODUCT OFFERINGS
TABLE 17 INOVIQ: MAJOR PRODUCT OFFERINGS
TABLE 18 LI-COR BIOSCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 19 NAUTILUS BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 20 PROTEOME FACTORY: MAJOR PRODUCT OFFERINGS
TABLE 21 QIAGEN: MAJOR PRODUCT OFFERINGS
TABLE 22 RHYTHM BIOSCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 23 SHIMADZU SCIENTIFIC INSTRUMENTS: MAJOR PRODUCT OFFERINGS
TABLE 24 SEER: MAJOR PRODUCT OFFERINGS
TABLE 25 WATERS: MAJOR PRODUCT OFFERINGS
TABLE 26 APPLIED BIOMICS: MAJOR SERVICE OFFERINGS
TABLE 27 CREATIVE PROTEOMICS: MAJOR SERVICE OFFERINGS
TABLE 28 POOCHON SCIENTIFIC: MAJOR SERVICE OFFERINGS
TABLE 29 SOMALOGIC: MAJOR SERVICE OFFERINGS
TABLE 30 VPROTEOMICS: MAJOR SERVICE OFFERINGS
TABLE 31 ABCAM: MAJOR PRODUCT OFFERINGS
TABLE 32 ANTEOTECH: MAJOR PRODUCT OFFERINGS
TABLE 33 AYOXXA BIOSCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 34 BIOGNOSYS: MAJOR PRODUCT OFFERINGS
TABLE 35 GENEI LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 36 GRACE BIO-LABS: MAJOR PRODUCT OFFERINGS
TABLE 37 ITSI-BIOSCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 38 MSAID: MAJOR PRODUCT OFFERINGS
TABLE 39 OLINK: MAJOR PRODUCT OFFERINGS
TABLE 40 PROMEGA: MAJOR PRODUCT OFFERINGS
TABLE 41 PROTEOMICS INTERNATIONAL: MAJOR PRODUCT OFFERINGS
TABLE 42 QUANTERIX: MAJOR PRODUCT OFFERINGS
TABLE 43 GLOBAL PROTEOMICS MARKET BY GEOGRAPHY 2021–2027 ($ BILLION)
TABLE 44 GLOBAL PROTEOMICS MARKET BY GEOGRAPHY 2021–2027 (%)
TABLE 45 GLOBAL PROTEOMICS MARKET BY PRODUCT 2021–2027 ($ BILLION)
TABLE 46 GLOBAL PROTEOMICS MARKET BY PRODUCT 2021–2027 (%)
TABLE 47 GLOBAL PROTEOMICS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 48 GLOBAL PROTEOMICS MARKET BY APPLICATION 2021–2027 (%)
TABLE 49 GLOBAL PROTEOMICS MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 50 GLOBAL PROTEOMICS MARKET BY END USER 2021–2027 (%)
TABLE 51 NORTH AMERICA PROTEOMICS MARKET BY PRODUCT 2021–2027 ($ BILLION)
TABLE 52 NORTH AMERICA PROTEOMICS MARKET BY PRODUCT 2021–2027 (%)
TABLE 53 NORTH AMERICA PROTEOMICS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 54 NORTH AMERICA PROTEOMICS MARKET BY APPLICATION 2021–2027 (%)
TABLE 55 NORTH AMERICA PROTEOMICS MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 56 NORTH AMERICA PROTEOMICS MARKET BY END USER 2021–2027 (%)
TABLE 57 EUROPE PROTEOMICS MARKET BY PRODUCT 2021–2027 ($ BILLION)
TABLE 58 EUROPE PROTEOMICS MARKET BY PRODUCT 2021–2027 (%)
TABLE 59 EUROPE PROTEOMICS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 60 EUROPE PROTEOMICS MARKET BY APPLICATION 2021–2027 (%)
TABLE 61 EUROPE PROTEOMICS MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 62 EUROPE PROTEOMICS MARKET BY END USER 2021–2027 (%)
TABLE 63 APAC PROTEOMICS MARKET BY PRODUCT 2021–2027 ($ BILLION)
TABLE 64 APAC PROTEOMICS MARKET BY PRODUCT 2021–2027 (%)
TABLE 65 APAC PROTEOMICS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 66 APAC PROTEOMICS MARKET BY APPLICATION 2021–2027 (%)
TABLE 67 APAC PROTEOMICS MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 68 APAC PROTEOMICS MARKET BY END USER 2021–2027 (%)
TABLE 69 LATIN AMERICA PROTEOMICS MARKET BY PRODUCT 2021–2027 ($ BILLION)
TABLE 70 LATIN AMERICA PROTEOMICS MARKET BY PRODUCT 2021–2027 (%)
TABLE 71 LATIN AMERICA PROTEOMICS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 72 LATIN AMERICA PROTEOMICS MARKET BY APPLICATION 2021–2027 (%)
TABLE 73 LATIN AMERICA PROTEOMICS MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 74 LATIN AMERICA PROTEOMICS MARKET BY END USER 2021–2027 (%)
TABLE 75 MIDDLE EAST & AFRICA PROTEOMICS MARKET BY PRODUCT 2021–2027 ($ BILLION)
TABLE 76 MIDDLE EAST & AFRICA PROTEOMICS MARKET BY PRODUCT 2021–2027 (%)
TABLE 77 MIDDLE EAST & AFRICA PROTEOMICS MARKET BY APPLICATION 2021–2027 ($ BILLION)
TABLE 78 MIDDLE EAST & AFRICA PROTEOMICS MARKET BY APPLICATION 2021–2027 (%)
TABLE 79 MIDDLE EAST & AFRICA PROTEOMICS MARKET BY END USER 2021–2027 ($ BILLION)
TABLE 80 MIDDLE EAST & AFRICA PROTEOMICS MARKET BY END USER 2021–2027 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
